We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street’s Radar. In this article, we are going to take a ...

Tempus AI’s diagnostic platform drives growth, but US healthcare reimbursement remains a hurdle. Learn why TEM stock is worth ...

We recently published a list of These 10 Firms Were Thursday’s Top Performers. In this article, we are going to take a look ...

In 2024, global and US markets saw a slight increase in IPOs. Syntax Data used its FIS classification system to analyze the ...

Ten companies, predominantly under the health, energy, and technology sectors—mirrored the gains on the back of stronger ...

No, public service shouldn’t require a vow of poverty. But when electeds get rich off stock trades based on inside info, it’s ...

Shares of Tempus AI climbed more than 5% on Thursday afternoon, poised for their longest winning streak since August 2024. The healthcare technology company has surged from $35 to $53 in just three ...

In the trial, patients who received a once-weekly 20 mg injection of amycretin over 36 weeks saw an impressive 22% reduction ...

In a report released today, Richard Hightower from Barclays maintained a Buy rating on Equity Residential (EQR – Research Report), with a price ...

Goldman Sachs analyst Stephen Laszczyk raised the firm’s price target on TKO Group (TKO) to $165 from $142 and keeps a Buy rating on the shares ...

InMed Pharmaceuticals Inc., a pharmaceutical company focusing on developing small molecule drug candidates for high unmet medical needs, recently announced the granting of an international Patent ...

The AMA and AHA, usually among the loudest advocates for their professions in any given national news cycle, are likely ...